Payment overview · 2025
General Payments
$319.45
17 reported records · 10 companies
Healthcare provider profile · identity verified
Joseph W Purcell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LANDING, NJ · NPI 1083676910
Verified facts
What the public records show
CMS Open Payments records show Joseph W Purcell, D.O. received $319.45 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.11 | 19.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.57 | 17.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.77 | 13.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.29 | 11.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.34 | 11.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.00 | 6.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.00 | 6.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.00 | 5.3% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.69 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.68 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $319.45 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $63.11 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $63.11 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $63.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $54.57 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 285 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 51 |
| Omeprazole | Omeprazole | 181 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 38 |
| Alprazolam | Alprazolam | 174 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 31 |
| Gabapentin | Gabapentin | 146 | 35 |
| Clonazepam | Clonazepam | 141 | 31 |
| Tramadol Hcl | Tramadol Hcl | 139 | 40 |
| Metformin Hcl Er | Metformin Hcl | 137 | 38 |
| Bupropion Xl | Bupropion Hcl | 117 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 33 |
| Trazodone Hcl | Trazodone Hcl | 109 | 33 |
| Potassium Chloride | Potassium Chloride | 107 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 103 | 15 |
| Lisinopril | Lisinopril | 99 | 30 |
| Losartan Potassium | Losartan Potassium | 99 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 28 |
| Carvedilol | Carvedilol | 87 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 25 |
| Diazepam | Diazepam | 83 | 13 |
| Meloxicam | Meloxicam | 83 | 26 |
| Glipizide Er | Glipizide | 71 | 21 |
| Azithromycin | Azithromycin | 69 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 19 |
| Metformin Hcl | Metformin Hcl | 68 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 14 |
| Methylprednisolone | Methylprednisolone | 61 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 56 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 16 |
| Prednisone | Prednisone | 52 | 26 |
| Furosemide | Furosemide | 51 | 15 |
| Montelukast Sodium | Montelukast Sodium | 51 | 15 |
| Morphine Sulfate | Morphine Sulfate | 46 | suppressed |
| Eliquis | Apixaban | 45 | 11 |
| Valacyclovir | Valacyclovir Hcl | 43 | 13 |
| Topiramate | Topiramate | 41 | 14 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Simvastatin | Simvastatin | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Etodolac | Etodolac | 31 | 12 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $319.45 · 17 records | PFIZER INC. | ABRYSVO, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Fluad, Flucelvax, GARDASIL 9, JARDIANCE, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, VAXELIS, VAXNEUVANCE, WELLBUTRIN, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error